GM-2505 is a psychedelic and experimental antidepressant that acts as a 5-HT2A and 5-HT2C receptor agonist and serotonin releasing agent.[1][2][3] Compared to other 5-HT2A receptor agonists, it is said to have a shorter duration of action.[3][4] It is under development by Gilgamesh Pharmaceuticals.[1] As of March 2024, GM-2505 is in phase 2 clinical trials for the treatment of major depressive disorder.[1] The chemical structure of GM-2505 does not yet seem to have been disclosed,[1] but disclosed compounds with the same mechanism of action have been patented by Gilgamesh in 2022.[5]
| Clinical data | |
|---|---|
| Routes of administration | Intravenous[1] |
| Drug class | Psychedelic; Serotonin 5-HT2A and 5-HT2C receptor agonist; Serotonin releasing agent |
| Legal status | |
| Legal status |
|
References
edit- ^ a b c d e "GM 2505". AdisInsight. 22 March 2024. Retrieved 30 August 2024.
- ^ Witkin JM, Golani LK, Smith JL (April 2023). "Clinical pharmacological innovation in the treatment of depression". Expert Rev Clin Pharmacol. 16 (4): 349–362. doi:10.1080/17512433.2023.2198703. PMID 37000975.
GM-2505 is a dual-acting compound with both agonist activity at 5-HT 2A receptors and a releaser of 5-HT. [...]
- ^ a b Conference-poster: Hughes, Zoe; Klein, Adam; Dvorak, Dino; Austin, Eric; Kiss, Laszlo; Marek, Gerard; Sporn, Jonathan; Kruegel, Andrew (2023). "22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy". Biological Psychiatry. 93 (9): S102–S103. doi:10.1016/j.biopsych.2023.02.262.
- ^ Beaney, Abigail (6 December 2023). "Gilgamesh to initiate Phase IIa trial of fast-acting psychedelic drug". Clinical Trials Arena. Retrieved 7 December 2023.
- ^ "Methods of treating mood disorders". Google Patents. 2022. Retrieved 14 November 2024.